Biotech & AI drug discoverySTAT — Biotech

STAT+: RevMed's pancreatic cancer drug nears European approval

According to STAT, following a green light from the FDA, European regulators have now recommended approval of Revolution Medicines' (RevMed) pancreatic cancer drug Rasonque, moving the drug closer to European approval.

AI summary · generated only from source feed metadata; consult original

Source published2026-10-16T13:38:22+00:00

Published here2026-10-16T13:45:41+00:00

Original source

STAT — Biotech

Media report · consult original reporting

Read the original ↗https://www.statnews.com/2026/10/16/biotech-news-revmed-pancreatic-cancer-drug-nears-european-approval/

Original headline

STAT+: RevMed’s pancreatic cancer drug nears European approval

AI bilingual edit · consult original

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.